SecBot SecBot
SECBOTREPLAY Home › Report › RIGL

RIGL · Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product…

RIGEL PHARMACEUTICALS INC · 8-K filed Aug 4, 2026 at 16:10 ET

At the news

MIXEDIMPACT 6/10

8-K filed Aug 4, 2026 at 16:10 ET

Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product sales $67.0M, +14% YoY) and EPS of $0.88, missing consensus of $0.91 by 3.3%. The company raised full-year 2026 revenue guidance to $285-295M (from $275-290M), reflecting strong core product sales momentum. The in-license of VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2- breast cancer, expands the commercial portfolio, but the $70M upfront payment drew down cash to $95.3M from $155M at year-end 2025.

  • Q2 2026 total revenues of $78.7M (net product sales $67.0M + contract revenue $11.7M)
  • Product sales grew 14% YoY; TAVALISSE +18%, REZLIDHIA +27%; GAVRETO -10%
  • GAAP diluted EPS $0.88 (consensus $0.91), 3.3% miss
  • Raised 2026 revenue guidance to $285-295M from prior $275-290M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access